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Abstract 
The CNS and gut peptide Neuromedin U (NMU) inhibits feeding following 
intracerebroventricular injection.  This study aimed to explore the hypothalamic actions of 
NMU on feeding and the hypothalamo-pituitary-adrenal (HPA) axis.  Intra-paraventricular 
nucleus (PVN) NMU dose-dependently inhibited food intake with a minimum effective dose 
of 0.1nmol and a robust effect at 0.3nmol.  Feeding inhibition was mapped by NMU injection 
into 8 hypothalamic areas.  NMU (0.3nmol) inhibited food intake in the PVN (0-1h: 59 ± 
6.9% control; p<0.001) and arcuate nucleus (0-1h: 76 ± 10.4% control; p<0.05).  Intra-PVN 
NMU markedly increased grooming and locomotor behavior and dose-dependently increased 
plasma ACTH (NMU 0.3nmol: 24.8 ± 1.9 vs. saline 11.4 ± 1.0 pg/ml, p<0.001) and 
corticosterone (NMU 0.3nmol: 275.4 ± 40.5 ng/ml vs. saline 129.4 ± 25.0 ng/ml, p<0.01).  
Using hypothalamic explants in vitro, NMU stimulated CRH (NMU 100nM: 5.9 ± 0.95 vs. 
basal 3.8 ± 0.39 pmol/explant, p<0.01) and AVP release (NMU 100nM: 124.5 ± 21.8 vs. 
basal 74.5 ± 7.6 fmol/explant, p<0.01) whilst leptin stimulated NMU release (141.9 ± 20.4 vs. 
basal 92.9 ± 9.4 fmol/explant, p<0.01).  Thus we describe a novel role for NMU in the PVN 






Neuromedin U (NMU) was first isolated from porcine spinal cord in 1985 and named for its 
potent contractile activity on the uterus (1).  Two molecular forms were purified; an 
octapeptide (NMU-8) and the N-terminally extended 25 amino acid form (NMU-25) (1).  
Both forms are biologically active, stimulating contraction of rat uterus in vitro and causing 
potent vasoconstriction in rats and dogs. (1-3).  Neuromedin U has since been fully sequenced 
in several species including dog (4), rabbit (5), frog (6) and human (7).  In rat a 23 amino acid 
peptide, NMU-23, is the naturally occurring form (8;9).  The C-terminal region of NMU is 
highly conserved between species.  Neuromedin U-like immunoreactivity (NMU-LI) is found 
in spinal cord, several brain regions including the hypothalamus, nerves throughout the 
gastrointestinal tract, the urogenital tract and the pituitary and thyroid glands (1;10-14).  The 
direct actions of NMU on the uterus, gut and vascular smooth muscle have been investigated 
(1-3).  However, despite the fact that NMU is an abundant hypothalamic peptide (14), a 
possible role for hypothalamic NMU is only just being explored. 
 
NMU-LI and mRNA expression are abundant in the central nervous system (CNS), 
particularly in nuclei of the brain stem and hypothalamus (13;15).  Within the hypothalamus 
NMU-immunoreactive cell bodies and mRNA expression are restricted to the arcuate nucleus 
(Arc) and median eminence (ME) (13;15).  The paraventricular nucleus (PVN), ventromedial 
nucleus (VMN), dorsomedial nucleus (DMN) and Arc receive dense innervation by NMU-
immunoreactive fibers (13).  This pattern of neuronal location and projection is similar to that 
of other neural networks thought to regulate food intake and body weight (16).  It has recently 
been shown that ICV administration of NMU inhibits food intake and that hypothalamic 
NMU mRNA expression is reduced by fasting and in the leptin-deficient ob/ob mouse (15), 
suggesting that hypothalamic NMU may play a role in appetite inhibition.  An aim of these 
studies was to further characterize the anorectic effect of NMU and its regulation by leptin.   
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Two G-protein coupled receptors, termed NMU1R and NMU2R, have been identified with a 
high affinity for NMU (15;17-20).  The NMU1R has a wide distribution in peripheral tissues 
including the gastrointestinal tract and adrenal cortex, but is not found in the CNS (15).  The 
NMU2R is found in a number of peripheral tissues but is also expressed in discrete CNS sites 
in rat and human (15).  Despite the fact that several hypothalamic nuclei, as described above, 
receive NMU projections, the only identified hypothalamic site of NMU2R expression is the 
PVN (15;21).  The PVN is important in the hypothalamic control of food intake (16).  Many 
peptides known to alter food intake influence feeding most potently in this nucleus (22-24).  It 
is also a key nucleus in the control of the hypothalamo-pituitary-adrenal (HPA) axis, being 
the site of corticotrophin releasing hormone (CRH) and arginine vasopressin (AVP) synthesis 
(25;26). 
 
Several observations suggest that NMU is linked to the HPA axis.  In the pituitary, NMU-LI 
is found in the majority of corticotrophs (27;28).  Also, NMU may act directly on the adrenal 
gland.  In vitro, NMU stimulates synthesis of steroids by adrenal slices, via a mechanism 
dependent upon the presence of medullary chromaffin cells (29).  In vivo, NMU increases 
plasma corticosterone and the volume of the zona fasiculata following subcutaneous 
administration for 6 days in rats (30).  It is not known whether NMU has a hypothalamic 
action on release of CRH or AVP and hence plasma concentration of adrenocorticotrophic 
hormone (ACTH) and adrenal steroids.  
 
The current study aimed to investigate the effect of NMU on the HPA axis at the 
hypothalamic level in vivo, by measuring the plasma ACTH and corticosterone response to 
NMU following direct administration into the PVN.  In order to explore the hypothalamic 
mechanism of action, the effect of NMU on release of CRH and AVP from hypothalamic 
explants in vitro was investigated.  Although the only confirmed hypothalamic site of NMU 
receptor expression is the PVN (15), NMU fibers project to several other hypothalamic nuclei 
(13).  We aimed to localize the hypothalamic site of action of NMU on food intake by using 
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microinjection into the hypothalamic sites which receive NMU-immunoreactive neuronal 
projections.  We also aimed to investigate whether ICV or intranuclear administration of 
NMU was associated with any changes in behavior other than feeding.  Hypothalamic 
explants in vitro were used to examine the effect of leptin on NMU release.  In this way we 
aimed to explore the site and mechanisms of the hypothalamic actions of NMU in regulation 




Materials and Methods 
Experimental Animals   Male Wistar rats (Imperial College, London, UK) weighing 200-
300g were maintained in individual cages (cannulated rats) or in cages of 5 (rats for in vitro 
experiments) under controlled temperature (21-23C) and light (12h light/dark cycle, lights 
on at 07.00h) with ad libitum access to food (RM1 diet, SDS UK Ltd.) and water.  All 
animal experimentation was conducted in accordance with accepted standards of humane 
animal care. 
Materials   Full length rat NMU (NMU-23) was custom synthesized (IAF Biochem, 
Quebec, Ontario, Canada) and used in all in vitro and in vivo experiments.  Leptin was 
purchased from R&D (Minneapolis, USA).  Reagents for basal hypothalamic explant 
experiments were supplied by BDH (Poole, Dorset, UK). 
ICV and intranuclear cannulation and injections 
Animal surgical procedures and handling were carried out as previously described (24;31).  
Animals were anaesthetized by intraperitoneal injection of a mixture of ketamine (Ketalar 60 
mg/kg, Parke-Davis, Pontypool, UK) and xylazine (Rompun 12 mg/kg, Bayer UK Ltd, Bury 
St. Edmunds, UK) and placed in a Kopf stereotaxic frame.  For ICV cannulation, permanent 
22 gauge stainless steel guide cannulae (Plastics One inc. Roanoke, VA) were placed into the 
third cerebral ventricle (0.8 mm posterior to the bregma on the mid-sagittal line 6.5 mm 
below the outer surface of the skull) (32).  For intranuclear cannulation, animals were 
implanted with 26-gauge stainless steel guide cannulae (Plastics One inc. Roanoke, VA) 
projecting to the Arc, PVN, VMN, DMN, medial preoptic area (MPO), supraoptic nucleus 
(SON), anterior hypothalamic area (AHA), and lateral hypothalamic area (LHA) of the 
hypothalamus, according to coordinates of Paxinos and Watson (figure 1) (32).  These areas 
were chosen as they all receive innervation with NMU-immunoreactive fibers (13).  All 
compounds were dissolved in 0.9 % saline and each study involved an injection of NMU or 
saline in a volume of 1 µl (intranuclear studies) or 5 µl (ICV studies) over 1 min.  NMU or 
saline were administered in the early light phase (09.00-10.00h) by a 31-gauge (for 
intranuclear studies) or a 27-gauge (for ICV studies) stainless steel injector placed in and 
 6
projecting 1mm below the tip of the cannulae.  Correct ICV cannula placement was 
confirmed by a positive dipsogenic response to angiotensin II (150ng/rat).  Only those 
animals with correct placement of cannulae were included in the data analysis.  Correct 
intranuclear cannula placement was confirmed histologically at the end of the study period.  
Following injection of 1µl Indian ink, animals were decapitated, guide cannulae removed and 
brains immediately frozen in liquid nitrogen and stored at –70C.  Brains were sliced on a 
cryostat (Bright, Huntingdon, UK) into 15µM coronal sections and stained with cresyl violet.  
Sections were compared with the corresponding section from the rat brain atlas of Paxinos 
and Watson.  The Indian ink remained localized at the injection site at the guide cannula tip 
without significant diffusion.  Data from an animal was excluded if its injection site extended 
more than 0.2mm outside the intended hypothalamic site of injection or if any Indian ink was 
detected in the cerebral ventricular system.  11.7±2.4% (mean±SEM) of cannulated animals 
were excluded due to cannula misplacement.   
Static Incubation of hypothalamic explants. 
Static incubation of hypothalamic explants was performed as previously described (33).  Male 
Wistar rats were killed by decapitation and the whole brain immediately removed.  The brain 
was mounted with ventral surface uppermost and placed in a vibrating microtome (Microfield 
Scientific Ltd., Dartmouth, UK).  A 1.7mm slice was taken from the basal hypothalamus and 
incubated in individual chambers containing 1ml of artificial cerebrospinal fluid (aCSF) 
(20mM NaHCO3, 126mM NaCl, 0.09mM Na2HPO4, 6mM KCl, 1.4mM CaCl2, 0.09mM 
MgSO4, 5mM glucose, 0.18mg/ml ascorbic acid and 100ug/ml aprotinin), equilibrated with 
95% O2 and 5% CO2.  The hypothalamic explant includes key nuclei involved in feeding and 
pituitary regulation, as shown in figure 1.  The tubes were placed on a shaking platform in a 
water bath maintained at 37C.  After an initial 2h equilibration period, the hypothalami were 
incubated for 45 min in 600µl aCSF (basal period) before being challenged with NMU (10, 
100 or 1000nM) or leptin (100nM) in 600µl aCSF.  Finally, the viability of the tissue was 
verified by a 45min exposure to aCSF containing 56mM KCl.  Isotonicity was maintained by 
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substituting K+ for Na+.  At the end of each period, the aCSF was removed and frozen at –20C 
until measurement of CRH, AVP and NMU by radioimmunoassay.  Our standard protocol for 
hypothalamic explants (33) is to use a peptide challenge at a concentration of approximately 
100x the IC50, ie 100nM for NMU (34).  We have found from previous experience that this 
concentration provides adequate stimulation, allowing for tissue penetration in hypothalamic 
explants.  Hypothalamic explants were also challenged with 10 fold higher and lower 
concentrations of NMU (10 and 1000nM) and the CRH and AVP responses measured.   
Investigation of the effect of ICV NMU on food intake and behavior.  Following an 
overnight fast, rats (n=13 per group) were injected in the early light phase with saline or 
NMU 1nmol and immediately returned to their home cages containing a pre-weighed amount 
of rat chow.  The dose of NMU chosen was based upon the lowest previously published dose 
of NMU to inhibit food intake (15).  Food was re-weighed at 1,2,4,8 and 24 hours post-
injection using an ATP Instrumentation GW 600 balance (ATP Instrumentations Ltd., Ashby-
de-la-Zouche, Leicestershire, UK) recording to the nearest 0.1g.  Rats (n=6 from each 
treatment group) were observed continuously for 1h post-injection by observers blinded to the 
experimental treatment.  Behavior was classified into seven different categories; feeding, 
drinking, grooming, rearing (defined as stationary with front paws elevated), head down 
(defined as stationary with all four paws on the cage bottom), locomotion (defined as moving 
around the cage, with all 4 paws moving) or sleeping (adapted from Fray et al (35)).  Each rat 
was observed for 15 sec every 5 min during the test session.  This 15 sec period was further 
divided into three 5 sec periods and the behavior of the rat scored in each section of the time 
period.  Each rat had a total of 36 behaviors recorded per hour.   
Investigation of the effect of NMU following micro-injection into specific hypothalamic 
nuclei.  A dose response study was performed to investigate the effects of NMU on food 
intake in the paraventricular nucleus, as this nucleus has been shown to express the NMU2R 
(15;21).  Following an overnight fast, rats (n=10-11 per group), cannulated into the PVN, 
were injected in the early light phase with saline or NMU (0.03, 0.1, 0.3 or 1.0nmol).  Food 
intake was measured as above. To investigate the effect of NMU on food intake in other 
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hypothalamic nuclei, separate groups of rats (n=12-15 cannulated into each nucleus) received, 
in random order, saline or NMU 0.3nmol by intranuclear micro-injection.  The dose of NMU 
chosen was based on previous experience suggesting that the effective intra-nuclear dose of a 
peptide on food intake is generally between one third and one tenth of the effective ICV dose 
(24;36;37) and on a dose giving a robust effect in the PVN dose response study.  The study 
was of randomized cross-over design.  Rats were injected in the early light phase (09.00 to 
10.00h), immediately returned to their home cages and food reweighed as above.  The 
methods for localization of neuropeptide effect by cannulation of multiple hypothalamic 
nuclei and injection of the neuropeptide of interest in a 1ul volume of vehicle is as established 
in previous studies (24;36;37).  Final numbers of animals included in data analysis for each 
nucleus were: PVN (13), LHA (14), MPO (12), DMN (15), AHA (15), SON (14), Arc (14), 
VMN (14).   
Investigation of the effect of intra-PVN microinjection of NMU on behavior. 
Following an overnight fast, a separate group of rats (n=6 per group), cannulated into the 
PVN, were injected in the early light phase with saline or NMU 0.3nmol and behavior was 
observed as described above. 
Investigation of the effect of NMU on the HPA axis.   
A separate group of PVN cannulated rats were injected in the early light phase (09.00-
10.00h) with saline or NMU 0.3nmol.  Rats were killed by decapitation at 5, 10, and 20 
minutes post-injection (n=9-10 per group at each time point).  A dose response curve was 
performed at the 20 minute time-point as stimulation of the HPA axis was shown at this 
time following injection of NMU 0.3nmol.  A further group of PVN-cannulated rats (n=10-
11 per group) were injected in the early light phase (09.00-10.00h) with saline or NMU 
(0.03, 0.1, 0.3 or 1.0nmol).  Rats were decapitated 20 minutes post-injection.  For both 
studies and trunk blood was collected into plastic lithium heparin and EDTA tubes 
containing 0.6mg aprotinin (Bayer, Haywards Heath, UK).  Plasma was separated by 
centrifugation, frozen and stored at –70C for subsequent ACTH measurement or –20C for 
subsequent corticosterone measurement by radioimmunoassay. 
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Radioimmunoassays 
ACTH was measured using a solid-phase immuno-radiometric assay (Euro-Diagnostica, 
Arnhem, the Netherlands).  Plasma corticosterone was measured using a commercially 
available radioimmunoassay (RIA) kit (ICN Biomedicals inc, USA).  CRH, AVP and NMU 
were measured using RIAs developed in the department and described previously elsewhere 
(10;38;39).  Briefly, CRH-like immunoreactivity (CRH-LI) was measured using an antibody 
raised in a rabbit immunized with synthetic CRH 41 conjugated to bovine serum albumin 
(BSA) by glutaraldehyde and used at a final dilution of 1:380000.  125I-[Tyr] CRH was 
labeled by the iodogen method and purified by reverse phase HPLC.  The assay was 
performed in a total volume of 0.35ml of 0.06 M phosphate EDTA buffer (pH 7.2) 
containing 0.1% BSA and 0.2% tween (1:10).  AVP-LI was measured using an antibody 
raised in a rabbit immunized with Arg8Vasopressin conjugated to BSA by carbodiimide 
technique and used at a final dilution of 1:64000.  125I Arg8vasopressin was labeled by the 
iodogen method and purified by reverse phase HPLC.  NMU-LI was measured using an 
antibody raised in a rabbit immunized with synthetic NMU-8 conjugated to BSA by 
glutaraldehyde and used at a final dilution of 1:56000. 125I-labeled NMU-8 tracer was 
prepared using chloramine-T technique and purified by reverse phase-HPLC.  The AVP and 
NMU assays were performed in a total volume of 0.7 ml of 0.06 M phosphate EDTA buffer 
(pH 7.2) containing 0.3% BSA.  All assays were incubated for 3-5 days at 4C before 
separation of free and antibody-bound label by dextran-coated charcoal 6mg/tube (BDH 
Norit, GSX), for NMU and AVP assays and sheep anti-rabbit antibody for CRH assay, 
followed by centrifugation at 2500 r.p.m.  Assay sensitivities were 2fmol/tube for CRH, 
0.5fmol/tube for AVP and 6fmol/tube for NMU (at 95% confidence limits).  The inter- and 
intra-assay coefficients of variation were less than 10% for CRH and AVP and 13 and 9% 
respectively for NMU.  The antibody used for AVP assay showed 50% cross-reactivity on a 
molar basis with lysine-vasopressin.  Other than this the antibodies used did not cross react 
with any known hypothalamic peptides.  
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Statistics 
Paired Student’s t test was used for comparison of peptide release from hypothalamic 
explants in the basal and stimulated periods and between saline and NMU treatment in the 
intranuclear cross-over study.  Unpaired Student’s t test was used for comparison of food 
intake between rats receiving saline or NMU 1nnol ICV.  One-way analysis of variance 
with post-hoc Tukey’s test was used for comparison of the effects on food intake and the 
HPA axis of intra-PVN administration of multiple doses of NMU to saline control.  As 
behavioral observation data were not normally distributed, Kruskall-Wallis test was used for 




Investigation of the effect of ICV NMU on food intake.   
In fasted rats, NMU (1nmol) significantly inhibited food intake in the first hour following 
ICV injection (3.8 ± 0.4g vs. saline control 5.4 ± 0.6g, p <0.05).  There was no significant 
difference in food intake between NMU and saline treatment groups at any subsequent time 
interval between 1 and 24 hours post-injection.   
 
Investigation of the effect of NMU on food intake following micro-injection into specific 
hypothalamic nuclei.   
Injection of NMU (0.03, 0.1, 0.3 or 1.0nmol) into the hypothalamic PVN resulted in dose 
dependent inhibition of food intake (figure 2a).  The lowest effective dose was 0.1nmol (0-1h 
food intake 6.4 ± 0.3g vs. saline control 8.2 ± 0.4g, p<0.05) with a robust effect at 0.3nmol 
(0-1h food intake 5.8 ± 0.5g, p<0.01 vs. saline control).   
 
To localize the hypothalamic site of the anorectic action of NMU, saline and NMU were 
injected into specific hypothalamic nuclei of fasted rats, in a randomized cross-over study 
design.  As these are paired observations, results are expressed as percentage of saline control.  
NMU caused inhibition of feeding at 1 hour following injection into the PVN (59 ± 6.9% 
control; p<0.001, figure 2b).  Inhibition of 0-1h food intake was also seen after intra-arcuate 
NMU administration (76 ± 10.4% control; p<0.05, figure 2b).  No immediate inhibition of 
feeding was seen following injection of NMU into any of the other hypothalamic areas (figure 
2b). 
 
Cumulative food intake following intra-PVN injection of NMU remained suppressed at 2, 4 
and 24 hours (figure 3a), however this was accounted for by the marked suppression of food 
intake in the first hour post-injection.  Following intra-arcuate NMU administration, 
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cumulative food intake after 1 hour was not significantly different from saline-treated controls 
(figure 3b).  A delayed suppression of cumulative food intake was noted following 
administration of NMU into the MPO (figure 3c).  This was accounted for by reduced food 
consumption between 4 and 8 hours post-injection (4.3 ± 0.7g vs saline 6.8 ± 0.6g, p<0.05) 
and during the dark phase between 8 and 24 hours post-injection (12.5 ± 1.5g vs saline 17.9 ± 
1.1g, p<0.05). 
 
Investigation of the effect of ICV and intra-PVN administration of NMU on behavior. 
The number of observations of each defined behavior was calculated and expressed as a 
percentage of the total number of observations in the hour after ICV or PVN injection of 
NMU or saline.  Following ICV administration of NMU 1.0 nmol or saline, there was a 
prompt, marked increase in grooming behavior (G) in NMU-treated compared to saline-
treated animals (median % of observations [inter-quartile range]: NMU 41.7% [20.8-54.2%]) 
vs. saline 8.3% [8.3-16.7%], p = 0.014).  In contrast, sleeping (S) was significantly reduced in 
NMU-treated rats (NMU 0%, [0-8.3%]) vs. saline 25% [25-41.7%], p = 0.026).  Despite the 
reduction in quantity of food eaten, there was no significant reduction in observed number of 
feeding (F) episodes in NMU-treated rats compared to saline-treated rats (data not shown).   
 
A similar pattern of marked behavioral change was noted in the hour after intra-PVN 
injection of NMU (figure 4).  A prominent increase in grooming (G) was observed (NMU 
52.8% [22.7-72.2%] vs. saline 5.6% [0-8.3%], p = 0.004).  NMU-treated animals also 
exhibited increased locomotor (L) behavior (NMU 20.8% [11.1-27.8%] vs. saline 0% [0-
2.8%], p = 0.011).  Conversely the quiescent behaviors of head down whilst still (H) and 
sleep (S) were reduced in NMU-treated animals (H: NMU 4.2% [2.8-25%] vs. saline 40.3% 
[36.1-41.7%], p= 0.03; S: NMU 0% [0-8.3%] vs. saline 51.4% [16.7-58.3%], p = 0.03).  
Despite the reduction in quantity of food eaten, there was no significant reduction in the 
observed number of feeding episodes in NMU-treated rats compared to saline-treated rats 
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(figure 4).  All behaviors observed were readily assigned to the pre-defined treatment 
categories and no adverse behaviors were observed in either treatment group. 
 
Investigation of the effect of NMU on the HPA axis 
Administration of NMU (0.03, 0.1, 0.3 and 1.0nmol) into the PVN dose-dependently 
stimulated the HPA axis with significant stimulation occurring at the 0.3 and 1.0nmol doses 
(figure 5).  NMU 0.3nmol significantly stimulated plasma ACTH (figure 5a: NMU 39.2 ± 5.9 
vs saline 12.2 ± 2.6 pg/ml, p<0.001) and corticosterone (figure 5b: NMU 303.6 ± 21.6 vs 
saline 171.0 ± 20.9 ng/ml, p<0.01) at 20 minutes post-injection.  No significant stimulation of 
ACTH or corticosterone was seen at 5 and 10 minutes post-injection of NMU 0.3nmol (data 
not shown). 
 
Investigation of NMU release from and NMU effect on hypothalamic explants in vitro. 
As a putative hypothalamic satiety signal we hypothesized that NMU release from its 
hypothalamic site of synthesis in the arcuate nucleus may be regulated by the peripheral 
satiety signal leptin.  Leptin (100nM) significantly stimulated release of NMU from medial 
basal hypothalamic explants in vitro (figure 6a: 141.9 ± 20.4 fmol/explant vs basal release of 
92.9 ± 9.4 fmol/explant, n=36; p<0.01). 
 
Hypothalamic explants were used to investigate whether stimulation of the HPA axis by 
NMU may be via release of CRH and/or AVP.  NMU (10, 100 and 1000nM) significantly 
stimulated release of CRH from medial basal hypothalamic explants in vitro (figure 6b, NMU 
100nM 5.9 ± 0.92 pmol/explant vs basal release of 3.8 ± 0.39 pmol/explant, n = 29; p<0.01).  
Similarly, NMU (10 and 100nM) stimulated AVP release (figure 6c, NMU 100nM 124.5 ± 




The current study adds to the accumulating body of evidence that NMU acts at the 
hypothalamic level to inhibit food intake (15; 20).  NMU may be a physiological regulator of 
feeding and body weight, as NMU-specific antibodies have been demonstrated to stimulate 
feeding (20).  Howard and co-workers first demonstrated that NMU inhibited food intake 
following ICV administration, but did not cause conditioned taste aversion (15).  They further 
demonstrated that hypothalamic NMU expression was reduced in rats following a 48-hour 
fast and in leptin-deficient ob/ob mice when compared to wild-type littermates (15).  We 
confirm that NMU inhibits food intake following ICV administration.   
 
In the current study we have administered NMU into discrete hypothalamic areas, to 
investigate whether the feeding inhibition can be localized to specific hypothalamic nuclei.  
An immediate inhibition of feeding was seen in the first hour following PVN and Arc 
administration of NMU.  No early inhibition of food intake was seen following injection of 
NMU into any of the other hypothalamic nuclei.  Following PVN injection of NMU there was 
inhibition of feeding to 59% of control food intake, compared with 76% following Arc 
injection.  Inhibition of food intake in the PVN was dose-dependent, with the lowest effective 
dose being NMU 0.1nmol.  The inhibition of feeding in the PVN may be mediated by the 
NMU2R.  Within the hypothalamus, in situ hybridization studies demonstrated that the 
NMU2R is expressed only in the PVN and in ependymal cells lining the third ventricle (15), 
whereas there is no hypothalamic expression of the NMU1R (15).  No NMU receptor 
expression has been demonstrated in the Arc.  It is possible that the NMU2R is expressed in 
the Arc at low levels not detectable by in situ hybridization.  Alternatively, the inhibition of 
feeding in this nucleus may be mediated by another, as yet unidentified, NMU receptor.  It is 
unlikely that the inhibition of feeding seen following arcuate injection of NMU is due to 
diffusion of peptide to the PVN.  No effect on food intake was seen following injection of 
NMU into the AHA, LHA, DMN and VMN, all of which are closer to the PVN.   
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 A surprising finding was the delayed inhibition of feeding seen at 4 to 8 hours and 8 to 24 
hours following NMU injection into the MPO.  The MPO is mainly involved in control of 
reproductive function, but c-fos-like immunoreactivity and NPY content increase in the MPO 
following ingestion of a palatable meal (40;41).  The anorectic hypothalamic peptide α-
melanocyte stimulating hormone also inhibits feeding when administered into the MPO (24).  
It is unlikely that the effect on food intake in the MPO is due to diffusion of peptide to the 
PVN, as no effect is seen until 4 hours.  Also, no similar effect was seen after injection of 
nuclei much closer to the PVN, such as the AHA.  It is possible that this delayed effect is 
indirect, involving the activation or inhibition of other neuronal regulatory systems.   
 
As NMU is a putative anorectic neurotransmitter, we investigated the effect of leptin on NMU 
release from hypothalamic explants.  Leptin stimulated NMU release in this system.  Others 
have shown that in the presence of low or absent circulating leptin (in fasting rats and in 
leptin deficient ob/ob mice) hypothalamic NMU expression is reduced (15).  These data, 
taken together, suggest that NMU release may be stimulated by leptin and NMU synthesis 
inhibited in its absence.   
 
The behavioral changes observed after administration of NMU, either ICV or into the PVN, 
were more striking than the inhibition of food intake.  Others have reported similar behavioral 
changes in response to ICV NMU (42).  It has been postulated that NMU caused locomotor 
and grooming behaviors via CRH neurons in the PVN, as the behavior pattern was similar to 
the stress response induced by ICV CRH (43-45).  Furthermore, the locomotor and grooming 
response to NMU was attenuated by the CRH antagonist alpha-helical CRH (9-41) or by anti-
CRH IgG (42).  The locomotor response to NMU was also absent in CRH knockout mice 
(42).  However CRH neurons involved in the stress response are also located in the central 
nucleus of the amygdala as well as the hypothalamic PVN (46).  It is possible that these 
neurons may have mediated the effect of ICV NMU.  We have now demonstrated that 
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administration of NMU directly into the PVN causes a marked increase in grooming and 
locomotor behavior.  Furthermore, NMU stimulates release of CRH as well as AVP from 
hypothalamic explants in vitro.  CRH has also been demonstrated to inhibit feeding after ICV 
administration (45).  Therefore, hypothalamic NMU has similar effects on feeding and stress-
related behaviors to CRH and appears to mediate these actions via the PVN, at least in part 
through CRH release.  We hypothesized that in addition to stimulating CRH neurons involved 
in arousal and stress-related behaviors, NMU may also stimulate the hypophysiotrophic 
CRH/AVP neurons responsible for activation of the HPA axis.  NMU administration into the 
PVN resulted in increased plasma ACTH and corticosterone at 20 minutes post-injection.  In 
combination with the finding that NMU increased release of CRH and AVP from 
hypothalamic explants in vitro, this suggests that CRH/AVP neurons projecting to the median 
eminence are NMU-responsive.  This is the first report that NMU stimulates the HPA axis at 
the hypothalamic level.   
 
The lowest effective doses of NMU in the in vivo and in vitro experiments were greater than 
the amount of NMU released from medial basal hypothalamic explants in vitro.  However, 
due to peptide degradation and the requirement for tissue penetration, the actual concentration 
of NMU reaching the NMUR on NMU-responsive neurons, both after ICV and intranuclear 
administration in vivo and after application to hypothalamic explants in vitro, will be less than 
the initial concentration administered.  Within the hypothalamus NMU appears to be 
restricted to a small sub-group of neurons with cell bodies in the Arc and median eminence 
(13;15) and with projections to several nuclei, particularly the PVN, VMN, DMN and Arc 
(13).  Whilst the total amount of NMU released from a hypothalamic explant in vitro may be 
relatively small, the concentration of NMU achieved in the synaptic cleft between NMU 
neurons and NMU target neurons is likely to be much higher.  It is possible that the 
concentration of NMU occurring physiologically at the NMUR of NMU-responsive neurons 
is comparable to that achieved after administration of effective doses of NMU in vivo and in 
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vitro.  At present, this remains speculative and the physiological significance of the actions of 
NMU described above remains to be established. 
 
In summary we present data to suggest that NMU inhibits food intake, via an action on the 
hypothalamic PVN and Arc.  Hypothalamic NMU release is stimulated by leptin, as would be 
expected for a putative satiety signal.  NMU inhibits feeding and stimulates stress-related 
behaviors and the HPA axis via an action on the PVN which appears to involve CRH release. 
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Figure 1 Diagrammatic representation of the hypothalamus (in coronal sections) 
showing the relationship of the nuclei cannulated and the approximate area contained in 
hypothalamic explants (bordered by dotted line).  3V = third cerebral ventricle, MPO = 
medial pre-optic area, SON = supra-optic nucleus, OC = optic chiasm, PVN = paraventricular 
nucleus, AHA = anterior hypothalamic area, DMH = dorsomedial hypothalamus, VMH = 
ventromedial hypothalamus, LHA = lateral hypothalamic area, Arc = arcuate nucleus 
 
Figure 2 (a) Food intake (mean grams per rat ± SEM) at 0-1hour following PVN 
injection of saline or NMU (0.03, 0.1, 0.3 or 1.0 nmol) in overnight fasted rats, n=10-11 per 
group.  (b) Food intake, expressed as percentage control (indicated by dotted line), at 0-1h 
following injection of NMU (0.3nmol) into the Arc, LHA, MPO, PVN, DMN, AHA, SON or 
VMN of overnight fasted rats, n=12-15 per group. *p<0.05, **p<0.01, ***p<0.001 vs. saline. 
 
Figure 3  Cumulative food intake up to 24 hours, expressed as % of saline control 
(indicated by dotted line), following microinjection of NMU (0.3nmol) into the a) PVN, b) 
Arc, c) MPO, d) AHA, e) LHA, f) DMN, g) SON, h) VMN of overnight fasted rats, n=12-15 
per group.   *p<0.05, **p<0.01, ***p<0.001 vs.saline. 
 
Figure 4 Pie charts depicting the proportion of observations of each of the pre-defined 
behaviors in the hour following intra-PVN injection of saline or NMU 0.3nmol, n=6 per 
group.  G = grooming, D = drinking (rat drinking from water bottle), F = feeding (rat eating 
chow), R = rearing (stationary with front paws lifted off cage floor), S = sleeping, H = head 
down (stationary with all four paws on cage floor), L = locomotor (moving about the cage). 
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Figure 5 Plasma concentration of (a) ACTH and (b) corticosterone at 20 minutes 
following intra-PVN administration of saline or NMU (0.03, 0.1, 0.3 or 1.0 nmol), n=10-11 
per group.  **p<0.01, *** p<0.001 vs. saline. 
 
Figure 6  (a) Quantity of NMU (fmol/explant) measured in aCSF harvested from 
hypothalamic explants (n=36) following a 45-minute basal incubation period and following a 
45-minute exposure to leptin 100nM in aCSF.  Quantity of (b) CRH (pmol/explant) and (c) 
AVP (fmol/explant) measured in aCSF harvested from hypothalamic explants following a 45-
minute basal incubation period and following a 45-minute exposure to NMU 10, 100 or 
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